Referencias: Guía detallada del cáncer de próstata

Akaza H, Hinotsu S, Usami M, et al; Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer. Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer. 2009;115:3437-3445.

Algotar AM, Thompson PA, Ranger-Moore J, et al. Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. Prostate. 2010;70:883-888.

American Cancer Society. Cancer Facts & Figures 2012. Atlanta, Ga: American Cancer Society; 2012.

American Cancer Society. Cancer Facts & Figures 2013. Atlanta, Ga: American Cancer Society; 2013.

American Joint Committee on Cancer. Prostate. In: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:457-464.

Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–1202.

Andriole GL, Grubb RL, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.

Barnas JL, Pierpaoli S, Ladd P, et al. The prevalence and nature of orgasmic dysfunction after radical prostatectomy. BJU Int. 2004;94:603-605.

Bostwick DG, Crawford ED, Higano CS, Roach M, eds. American Cancer Society’s Complete Guide to Prostate Cancer. Atlanta, Ga: American Cancer Society; 2005.

De Bono JS, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). J Clin Oncol 28:7s, 2010 (suppl; abstr 4508).

de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995-2005.

Epstein JI. An update of the Gleason grading system. J Urol. 2010;183:433-440.

Fizazi K, Bosserman L, Gao G, et al. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: Results of a randomized phase II trial. J Urol. 2009;182:509-515.

Giovanucci E, Platz EA. Epidemiology of prostate cancer. In: Vogelzang NJ, Scardino PT, Shipley WU, Debruyne FMJ, Linehan WM, eds. Comprehensive Textbook of Genitourinary Oncology. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2006:9-21.

Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670-3679.

Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.

Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:1099-1105.

Klein EA, Thompson IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306:1549-1556.

Kyrgidis A, Vahtsevanos K, Koloutsos G, et al. Bisphosphonate-related osteonecrosis of the jaws: A case-control study of risk factors in breast cancer patients. J Clin Oncol. 2008;26:4634-4638.

Lin DW. Beyond PSA: Utility of novel tumor markers in the setting of elevated PSA. Urol Oncol. 2009;27:315-321.

Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301:39-51.

Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300:173-181.

Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:1375-1383.

Nanda A, Chen MH, Moran BJ, et al. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2010;76:1439-1444.

National Cancer Institute. Physician Data Query (PDQ). Prostate Cancer Treatment. 2011. Accessed at www.cancer.gov/cancertopics/pdq/treatment/prostate/healthprofessional on December 6, 2011.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Prostate Cancer. Version 4.2011. Accessed at www.nccn.org/professionals/physician_gls/pdf/prostate.pdf on December 6, 2011.

Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: A review. Cancer. 2008;113:1097-1106.

Nelson WG, Carter HB, DeWeese TL, et al. Prostate Cancer. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Kastan MB, McKenna WG, eds. Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:1653-1699.

Ornish D, Weidner G, Fair WR, et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol. 2005;174:1065-1069.

Potosky AL, Davis WW, Hoffman RM. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: The Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2004;96:1358-1367.

Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.

Price MM, Hamilton RJ, Robertson CN, Butts MC, Freedland SJ. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. Urology. 2008;71:787-791.

Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med. 2012 Dec 10. [Epub ahead of print]

Quinlan DM, Epstein JI, Carter BS, Walsh PC. Sexual function following radical prostatectomy: Influence of preservation of neurovascular bundles. J Urol. 1991;145:998-1002.

Savoie M, Kim SS, Soloway MS. A prospective study measuring penile length in men treated with radical prostatectomy for prostate cancer. J Urol. 2003;169:1462-1464.

Scher HI, Fizazi K, Saad F, et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15.

Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.

Shinohara K, Master VA, Chi T, Carroll PR. Prostate needle biopsy techniques and interpretation. In: Vogelzang NJ, Scardino PT, Shipley WU, Debruyne FMJ, Linehan WM, eds. Comprehensive Textbook of Genitourinary Oncology. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2006:111-119.

Smith MR, Egerdie B, Hernández Toriz N, et al; Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;36:745-755.

Sun M, Lughezzani G, Alasker A, et al. Comparative study of inguinal hernia repair after radical prostatectomy, prostate biopsy, transurethral resection of the prostate or pelvic lymph node dissection. J Urol. 2010;183:970-975.

Wolf A. Wender RC, Etzoni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: Update 2010. Ca Cancer J Clin. 2010;60:70-98.

Zelefsky MJ, Eastham JA, Sartor OA, Kantoff P. Cancer of the prostate. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Lippincott-Raven; 2008:1392-1452.